Hancock, Kerry L.Bosnic-Anticevich, Sinthia ZBlakey, JohnHew, MarkChung, Li PingCvetkovski, BiljanaClaxton, ScottDel Fante, PeterDenton, EveDoan, JoeRanasinghe, KanchanamalaMorgan, LucySharma, AnitaSmith, Peter KStewart, DebThompson, Philip JWiseman, RussellUpham, John WYan, Kwok YinCarter, VictoriaDhillon , KiranjeetHeraud, FlorianLe, ThaoVella, RebeccaPrice, David2022-07-052022-07-052022-07-05Hancock, K L, Bosnic-Anticevich, S Z, Blakey, J, Hew, M, Chung, L P, Cvetkovski, B, Claxton, S, Del Fante, P, Denton, E, Doan, J, Ranasinghe, K, Morgan, L, Sharma, A, Smith, P K, Stewart, D, Thompson, P J, Wiseman, R, Upham, J W, Yan, K Y, Carter, V, Dhillon , K, Heraud, F, Le, T, Vella, R & Price, D 2022, 'Characterisation of the Australian adult population living with asthma : Severe exacerbation frequency, long-term OCS use and adverse effects.', Pragmatic and Observational Research, vol. 2022, pp. 43-58. https://doi.org/10.2147/POR.S3600441179-7266https://hdl.handle.net/2164/18789Acknowledgements We wish to acknowledge and thank Sheryl Bradley, Rob Campbell, Andrew Davis, Sophie Jones, Chi Ming Lau, Ying Liu, Ian Miles, Marion Magee, Dominique Novic, John Pakos, Frank Postma, Dr Ondrej Rejda, Josephine Samuel-King, David Smallwood, Shay Soremekun, Majella Soumakiyan, Lisa Sugg, and Bruce Willet of the OPCA Improving Asthma outcomes in Australia Research Group for their valuable contributions in making this publication possible. AstraZeneca was given the opportunity to review the manuscript for medical and scientific accuracy, but the authors retained full editorial control. We wish to acknowledge Clare Ghisla, Amanda Baker, and Robin Whiteley for their academic contribution. Writing, editorial support, and/or formatting assistance in the development of this manuscript was provided by Shilpa Suresh, MSc, of the Observational and Pragmatic Research Institute, Singapore.162207881engAsthmaexacerbationsoral corticosteroidsadultsAustraliaR MedicineSupplementary InformationRJournal article10.2147/POR.S360044